AJANTPHARM / Q4-FY26 / claim-ledger

Audit the questions that mattered.

Ajanta Pharma · Analyst questions, management answers, and the quality of the response where the ledger is available.

Research layer active

ConCallIQ research layer

Signal, with the source still visible.

Use the controls below to narrow the view, then follow the evidence into the next layer of context.

PositiveQ4-FY26 · 2026-05-15Back to quarter ↗

Questions audited

Answered directly

88%

Numeric claims

Consistency

contradicted

Question ledger

What was answered, and how?

Siddharth Meghani · CWC

direct

PCPM in domestic business and generic semaglutide opportunity outside India.

On the productivity, the PCPM for the last full year has worked out to INR 3.7 lakhs per man per month. ... Outside of India, we are going to start our filing this quarter. Normally the approvals takes somewhere between 1.5 years to 2 years.

Avnish Baramal · Waikeria

direct

Impact of Middle East conflict on costs and ability to pass on increases.

The freights have increased, both air and sea across geographies. ... It is absorbed by us in our P&L. ... It is absorbed by the manufacturing companies.

Tushar Manudhane · Motilal Oswal

direct

Why EBITDA margin guidance is lower at 27% for FY27 vs 27.7% in FY26.

we are investing quite a bit on the market in terms of drug registration, in terms of MR addition across the markets. ... we are also proposing to increase the filing across the markets, so that also will increase the R&D cost little bit.

Tushar Manudhane · Motilal Oswal

direct

Number of MRs to be added in India for FY27.

About, I think about 5%-6% is something which we are looking at. In the range of 250-300 MRs.

Tushar Manudhane · Motilal Oswal

partial

Inventory days for U.S. market.

We don't give out such a breakup of the inventories market-wise. ... Normally we carry about 3 months inventory.

Abdulkader Puranwala · ICICI Securities

direct

Slowdown in India business in Q4 and expected bounce back.

If you look at the annualized performance, we have recorded 14% growth, which is significantly higher than the IPM growth rate. ... This one quarter has been an aberration due to inexplicable kind of reasons.

Abdulkader Puranwala · ICICI Securities

direct

Asia business performance and timeline for growth recovery.

We have seen that the logistics have been now streamlined. ... we are looking that in the next year our guidance for the Asia is in the high double digits.

Abdulkader Puranwala · ICICI Securities

direct

U.S. business trajectory and confidence in sustaining over 500 crore revenue.

going forward for the next year, we are looking at a mid-single-digit growth for the U.S. business, considering that for the whole year we have delivered an extremely robust growth of 49%.

Bino Pathiparampil · Elara Capital

direct

How are shipments to Middle East happening?

the logistics have settled. It is just, it is taking longer and cost has gone up significantly.

Udhayaprakash J · Value Research

declined

Revenue generated by new product launches over last two years.

That figure, we don't have it at hand at this moment. I would encourage you to email it to the investor relations team, and we'll come back to you.

Udhayaprakash J · Value Research

direct

Reason for increase in promoter pledge level.

two other brothers who are developing their new businesses. For their new businesses, they are pledging the share and borrowing for that. Nothing to do with Ajanta Pharma borrowing at all.

Forum Parekh · PoB Capital

direct

Reason for spike in receivable days and new normal.

this is mainly because of the higher sales at U.S. ... I think we can consider this as a new normal now.